Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Leases (2023 - 2025)

Monte Rosa Therapeutics' Current Leases history spans 3 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Current Leases rose 18.39% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, up 18.39%, while the annual FY2025 figure was $4.4 million, 18.39% up from the prior year.
  • Current Leases reached $4.4 million in Q4 2025 per GLUE's latest filing, up from $4.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.4 million in Q4 2025 to a low of $2.7 million in Q2 2023.
  • Average Current Leases over 3 years is $3.5 million, with a median of $3.6 million recorded in 2024.
  • Peak YoY movement for Current Leases: soared 30.15% in 2024, then rose 15.55% in 2025.
  • A 3-year view of Current Leases shows it stood at $3.2 million in 2023, then rose by 17.46% to $3.7 million in 2024, then increased by 18.39% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Current Leases are $4.4 million (Q4 2025), $4.2 million (Q3 2025), and $4.1 million (Q2 2025).